Muhammet Ozer

Heme/Onc Fellow @UTSWCancer

[Muhammet Ozer @MuhammetOzerMD]

Honored and grateful to receive the 2026 Outstanding Achievement in Patient Care Award @utswcancer @UTSWMedCenter.

This award means so much because it recognizes what first drew me to oncology: caring for patients with compassion and purpose.

#MedTwitter #HemeOnc #UTSW

[Muhammet Ozer @MuhammetOzerMD]

Thrilled and honored to be selected for the 2026 AACR/ASCO Methods in Clinical Cancer Research Workshop in Vail! This is especially meaningful as a 1st-year fellow @utswcancer . Excited to develop my #clinicaltrial protocol with @AACR / @ASCO faculty! #AACR #ASCO

[Tim Brown, MD MSCE @TimothyJBrownMD]

Thrilled to share our piece in @JCO_ASCO “Has Colorectal Cancer (c-)Met Its Match With Telisotuzumab Adizutecan?”
@MuhammetOzerMD @UGrewalMD @GIMedOnc @TheGutOncLab
https://t.co/81UWbI5Yc3

[Tim Brown, MD MSCE @TimothyJBrownMD]

Sharing our latest article with @MuhammetOzerMD out in @JCOOP_ASCO “Repurposing Renin-Angiotensin System Inhibitors in Colon Cancer: Signal, Plausibility, and the Need for Prospective Validation”, discussing drug repurposing in oncology @TheGutOncLab

https://t.co/LCbprhiEUW

[Muhammet Ozer @MuhammetOzerMD]

Sharing our ASCO Daily News piece on #KRAS G12C–mutant #CRC, focused on combination therapies & addressing resistance. 🚀 #ASCODailyNews @ASCO @TimothyJBrownMD @utswcancer
https://t.co/E9DGjKERZv

[Muhammet Ozer @MuhammetOzerMD]

Presenting at #GI26 @ASCO. Honored to receive a @ConquerCancerFd Merit Award🎖️. Phase II study of ATRA + atezolizumab + bevacizumab in refractory MSS #mCRC. Manageable, mostly low-grade #AEs. Efficacy data forthcoming🎢 | Great mentorship from @SyedKazmiMD @utswcancer

[Brandon Rose, MD, MPH @BRoseMDMPH]

HER2 discordance in UGI cancers 🙅‍♂️Got lots of foot traffic and interesting questions 🧐 Manuscript in progress 📝 Great leadership from the idea man @TimothyJBrownMD 🤠. @TheGutOncLab. @UTSWHemeOnc @MuhammetOzerMD @UGrewalMD